When a stock nearly triples in its first year as a public company, people tend to notice. That was the case with Inari Medical (NASDAQ: NARI) . The company went from one analyst covering it last year to six -- all but one with a buy rating -- heading into its first quarter earnings report this May. Despite posting robust growth, the stock has gotten crushed in the months since. Its most recent results only worsened the skid.
Now, with the stock down 43% from its highs, the six analysts that cover Inari have a median price target of $119 per share. The highest is predicting $140 -- that's almost double the current price. Let's dig in to see if that's a realistic expectation or if downgrades may be on the horizon.
Image source: Getty Images.
For further details see:
Wall Street Thinks This Healthcare Stock Could Double Your Money in the Next Year